Kala Pharmaceuticals, Inc. (KALA)

Kala Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	3.89	11.24	6.36	6.07
Revenue Growth (YoY)	-	-	-65.37%	76.67%	4.74%	-
Cost of Revenue	0	0	2.56	4.1	3.17	2.01
Gross Profit	0	0	1.33	7.14	3.19	4.07
Selling, General & Admin	19.96	20.57	65.04	105.06	81.07	65.02
Research & Development	20.9	18.59	17.65	11.52	18.35	27.28
Other Operating Expenses	0	-0.23	0.64	20.81	0	0
Operating Expenses	40.86	38.92	83.33	137.39	99.42	92.29
Operating Income	-40.86	-38.92	-81.99	-130.25	-96.23	-88.22
Interest Expense / Income	5.8	5.81	7.27	8.38	8.59	8.48
Other Expense / Income	-7.1	-2.54	-44.44	3.98	-0.49	-2.36
Pretax Income	-39.55	-42.2	-44.82	-142.61	-104.33	-94.35
Net Income	-39.55	-42.2	-44.82	-142.61	-104.33	-94.35
Shares Outstanding (Basic)	3	2	2	1	1	1
Shares Outstanding (Diluted)	3	2	2	1	1	1
Shares Change	35.96%	59.94%	15.50%	25.67%	53.11%	27.87%
EPS (Basic)	-14.96	-17.35	-29.48	-108.32	-99.50	-138.00
EPS (Diluted)	-14.96	-17.35	-29.48	-108.32	-99.50	-138.00
Free Cash Flow	-29.56	-28.49	-79.11	-109.03	-92.64	-94.06
Free Cash Flow Per Share	-10.51	-11.71	-52.02	-82.82	-88.43	-137.47
Gross Margin	-	-	34.22%	63.55%	50.13%	66.94%
Operating Margin	-	-	-2106.73%	-1158.76%	-1512.59%	-1452.49%
Profit Margin	-	-	-1151.64%	-1268.73%	-1639.85%	-1553.29%
Free Cash Flow Margin	-	-	-2032.55%	-970.01%	-1456.08%	-1548.49%
EBITDA	-33.22	-35.91	-36.58	-131.92	-92.9	-83.25
EBITDA Margin	-	-	-939.88%	-1173.62%	-1460.20%	-1370.61%
Depreciation & Amortization	0.53	0.47	0.98	2.31	2.84	2.62
EBIT	-33.76	-36.39	-37.56	-134.23	-95.74	-85.87
EBIT Margin	-	-	-964.95%	-1194.17%	-1504.84%	-1413.68%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).